{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:13:10Z","timestamp":1789726390098,"version":"4.0.1"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Teicoplanin is used to treat serious Gram-positive bacterial infections. However, the optimal trough concentrations for pediatric patients remain unclear owing to the lack of monitoring guidelines. This study aimed to determine the optimal teicoplanin trough concentration for treating Gram-positive bacterial infections in children.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic review was conducted using 4 databases. Stepwise cutoffs within the range of 10\u201330 mcg\/mL were used for efficacy and safety. Studies were included if they reported treatment success rates and\/or all-cause mortality, nephrotoxicity, hepatotoxicity, and thrombocytopenia according to the trough concentration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The meta-analysis included 12 studies involving 830 pediatric patients. Teicoplanin cutoff values of 10, 15, 20, and 30 mcg\/mL were reported in 9, 8, 9, and 2 studies, respectively. Trough concentrations &lt;10 mcg\/mL significantly reduced the treatment success rate, with an odds ratio of 0.07 and a 95% confidence interval ranging from 0.01 to 0.40. The overall treatment success rate was 50.0% versus 95.7% observed at concentrations \u226510 mcg\/mL. However, no significant difference was observed at the 15-, 20-, and 30-mcg\/mL cutoffs, when compared with lower concentrations. Trough concentrations &lt;20 mcg\/mL were associated with a decreased risk of nephrotoxicity (odds ratio = 0.21; 95% confidence interval, 0.08\u20130.55). However, hepatotoxicity and thrombocytopenia showed no significant associations with trough concentration ranges between 10 and 30 mcg\/mL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Although further prospective studies are required for validation, the authors' findings suggest that 10- to 20-mcg\/mL teicoplanin is the optimal trough concentration for enhanced clinical success and reduced toxicity in pediatric patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001230","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T14:16:18Z","timestamp":1721312178000},"page":"699-709","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Optimal Teicoplanin Trough Concentration With Therapeutic Drug Monitoring in Children: A Systematic Review and Meta-analysis"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4606-7150","authenticated-orcid":false,"given":"Yuki","family":"Hanai","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Uekusa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Toho University Omori Medical Centre, Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Toho University Omori Medical Centre, Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Takesue","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Japan;"},{"name":"Department of Clinical Infectious Diseases, Tokoname City Hospital, Tokoname, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1086\/675836","article-title":"Healthcare-associated bloodstream infections in a neonatal intensive care unit over a 20-year period (1992-2011): trends in incidence, pathogens, and mortality","volume":"35","author":"Verstraete","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.spid.2006.06.005","article-title":"Coagulase-negative staphylococcal infections in the neonate and child: an update","volume":"17","author":"Venkatesh","year":"2006","journal-title":"Semin Pediatr Infect Dis"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4067\/s0716-10182018000200140","article-title":"Microorganismos aislados de hemocultivos en ni\u00f1os con c\u00e1ncer y neutropenia febril de alto riesgo en cinco hospitales de Santiago, Chile, per\u00edodo 2012-2015","volume":"35","author":"Maldonado","year":"2018","journal-title":"Revista chilena de infectolog\u00eda"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"e1294","DOI":"10.1542\/peds.2009-2867","article-title":"Antibiotic management of Staphylococcus aureus infections in US children's hospitals, 1999-2008","volume":"125","author":"Herigon","year":"2010","journal-title":"Pediatrics"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jac\/37.2.209","article-title":"The comparative efficacy and safety of teicoplanin and vancomycin","volume":"37","author":"Wood","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"R6-20250603","first-page":"CD007022","article-title":"Teicoplanin versus vancomycin for proven or suspected infection","volume":"6","author":"Cavalcanti","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1128\/AAC.34.11.2114","article-title":"Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses","volume":"34","author":"Outman","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-200039030-00001","article-title":"Clinical pharmacokinetics of teicoplanin","volume":"39","author":"Wilson","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2165\/00003495-199447050-00008","article-title":"Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy","volume":"47","author":"Brogden","year":"1994","journal-title":"Drugs"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jac\/dkg147","article-title":"Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose","volume":"51","author":"Pea","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.medmal.2013.05.008","article-title":"Inter-individual and intra-individual pharmacokinetic variability during teicoplanin therapy in geriatric patients","volume":"43","author":"Uhart","year":"2013","journal-title":"M\u00e9decine et Maladies Infectieuses"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","article-title":"The clinical relevance of plasma protein binding changes","volume":"52","author":"Roberts","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/bcp.12710","article-title":"Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease","volume":"80","author":"Zhao","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/INF.0000000000001456","article-title":"Evaluation of teicoplanin trough values after the recommended loading dose in children with associated safety analysis","volume":"36","author":"Yamada","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/jac\/39.6.789","article-title":"The pharmacokinetics of teicoplanin in infants and children","volume":"39","author":"Reed","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1128\/AAC.03685-14","article-title":"Population pharmacokinetics of teicoplanin in children","volume":"58","author":"Ramos-Mart\u00edn","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/jcpt.13366","article-title":"Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: a systematic review and meta-analysis","volume":"46","author":"Hanai","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ijantimicag.2014.07.005","article-title":"Evaluation of teicoplanin concentrations and safety analysis in neonates","volume":"44","author":"Yamada","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.3346\/jkms.2020.35.e376","article-title":"Therapeutic drug level monitoring of teicoplanin in Korean pediatric patients with normal versus impaired renal function","volume":"35","author":"Choi","year":"2020","journal-title":"J Korean Med Sci"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.2147\/IDR.S272982","article-title":"Therapeutic drug monitoring and nephrotoxicity of teicoplanin therapy in Chinese children: a retrospective study","volume":"13","author":"Sun","year":"2020","journal-title":"Infect Drug Resist"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/jpids\/piab005","article-title":"Teicoplanin therapeutic drug monitoring and treatment outcomes in children with gram-positive infections","volume":"10","author":"Loane","year":"2021","journal-title":"J Pediatr Infect Dis Soc"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jiac.2015.02.002","article-title":"Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections","volume":"21","author":"Nakamura","year":"2015","journal-title":"J Infect Chemother"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/jac\/dkq266","article-title":"Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service","volume":"65","author":"Tobin","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/00006454-199606000-00005","article-title":"Teicoplanin pharmacokinetics in pediatric patients","volume":"15","author":"Dufort","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jac\/dkab499","article-title":"Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"77","author":"Hanai","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"Robins-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"key":"R31-20250603","first-page":"656","article-title":"Pharmacokinetic and clinical studies on teicoplanin for sepsis by methicillin-cephem resistant Staphylococcus aureus in the pediatric and neonate field","volume":"55","author":"Sunakawa","year":"2002","journal-title":"Jpn J Antibiot"},{"key":"R32-20250603","first-page":"215","article-title":"A combination therapy consisting of teicoplanin for febrile neutropenia in pediatric patients with malignancy","volume":"20","author":"Okuda","year":"2006","journal-title":"Jpn J Pediatr Hematol"},{"key":"R33-20250603","first-page":"78","article-title":"Evaluation of the efficacy and safety of teicoplanin administration for low-birth-weight infants","volume":"31","author":"Moriyama","year":"2019","journal-title":"J Jpn Soc Neonatal Health Dev"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s10156-012-0458-8","article-title":"Pharmacokinetics of glycopeptide antibiotics in children","volume":"19","author":"Ito","year":"2013","journal-title":"J Infect Chemother"},{"key":"R35-20250603","first-page":"7","article-title":"Four times loading dose of teicoplanin achieves an effective serum concentration in pediatric cases","volume":"63","author":"Kataoka","year":"2015","journal-title":"Jpn J Chemother"},{"key":"R36-20250603","first-page":"376","article-title":"Safety analysis of teicoplanin trough concentrations of over 15 \u03bcg\/mL, and evaluation of the recommended loading dose regimen to rapidly achieve optimal concentrations in pediatric patients","volume":"67","author":"Hironaka","year":"2019","journal-title":"Jpn J Chemother"},{"key":"R37-20250603","first-page":"387","article-title":"Rate of achievement of serum teicoplanin trough concentrations of \u226515 \u03bc g\/mL, and investigation of factors that cause serum teicoplanin trough concentrations to fluctuate after a loading dose regimen in pediatric malignancy patients","volume":"70","author":"Arima","year":"2022","journal-title":"Jpn J Chemother"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/jac\/dkp147","article-title":"Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme","volume":"64","author":"Lamont","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.3346\/jkms.2023.38.e62","article-title":"Optimal use and need for therapeutic drug monitoring of teicoplanin in children: a systematic review","volume":"38","author":"Choi","year":"2023","journal-title":"J Korean Med Sci"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5414\/CP202247","article-title":"Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections","volume":"53","author":"Wang","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jac\/45.6.835","article-title":"Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome","volume":"45","author":"Harding","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1128\/AAC.34.12.2392","article-title":"Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin","volume":"34","author":"Greenberg","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 6","key":"R43-20250603","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00003495-199700546-00006","article-title":"Management of serious staphylococcal infections in the outpatient setting","volume":"54","author":"Graninger","year":"1997","journal-title":"Drugs"},{"issue":"suppl 4","key":"R44-20250603","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.ijid.2010.05.006","article-title":"Consensus document on controversial issues in the diagnosis and treatment of bloodstream infections and endocarditis","volume":"14","author":"Boumis","year":"2010","journal-title":"Int J Infect Dis"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40360-020-00424-3","article-title":"Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 \u03bcg\/mL using a regimen of 12 mg\/kg for five doses within the initial 3 days","volume":"21","author":"Ueda","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0924-8579(98)00025-9","article-title":"Comparative safety of teicoplanin and vancomycin","volume":"10","author":"Wilson","year":"1998","journal-title":"Int J Antimicrob Agents"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bcpt.13679","article-title":"Clinical predictors of nephrotoxicity associated with teicoplanin: meta-analysis and meta-regression","volume":"130","author":"Hirai","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"suppl 1","key":"R48-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0924-8579(94)90049-3","article-title":"A critical review of the dosage of teicoplanin in Europe and the USA","volume":"4","author":"Wilson","year":"1994","journal-title":"Int J Antimicrob Agents"},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/jac\/dkaa385","article-title":"Nephrotoxicity of concomitant piperacillin\/tazobactam and teicoplanin compared with monotherapy","volume":"76","author":"Workum","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijantimicag.2018.11.002","article-title":"Impact of piperacillin\/tazobactam on nephrotoxicity in patients with Gram-negative bacteraemia","volume":"53","author":"Hall","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: nephrotoxicity","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ijantimicag.2014.01.023","article-title":"Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study","volume":"43","author":"Roberts","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ijantimicag.2015.01.015","article-title":"Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis","volume":"45","author":"Brink","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jiac.2020.06.006","article-title":"Teicoplanin and therapeutic drug monitoring: an update for optimal use in different patient populations","volume":"26","author":"Pea","year":"2020","journal-title":"J Infect Chemother"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:12:22Z","timestamp":1748970742000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001230","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"2024-02-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}